Business
Cell Source, Inc.: Clinical trials for our product candidates are expensive and time consuming and their outcome is uncertain.
Net income increased 15.2% to ($4.5M), while Operating cash flow decreased 14.3% to ($2.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2024 revenue N/AWatch
- Profitability — Net income ($4.5M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Latest filings
- 10-Q · Quarterly report2026-05-14
- 10-K · Annual report2026-04-07
- 8-K · Company announcement2025-06-27
- 10-Q · Quarterly report2024-11-14
- 10-Q · Quarterly report2024-08-19
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cell Source, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.